Acorafloxacin
- Generic Name
- Acorafloxacin
Efficacy and Safety Study of JNJ-32729463 Compared With Moxifloxacin for the Treatment of Subjects Requiring Hospitalization for Community-Acquired Bacterial Pneumonia
Phase 2
Terminated
- Conditions
- Community-Acquired Bacterial Pneumonia (CABP)
- Interventions
- First Posted Date
- 2010-09-10
- Last Posted Date
- 2011-12-08
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 32
- Registration Number
- NCT01198626
- Locations
- 🇵🇱
Furiex Research Site, Warszawa, Poland
Efficacy and Safety Study of JNJ-32729463 for Treating Complicated Skin and Skin Structure Infections Compared to Linezolid (Zyvox)
Phase 2
Completed
- Conditions
- Complicated Skin and Skin Structure Infections
- Interventions
- First Posted Date
- 2010-05-24
- Last Posted Date
- 2011-12-16
- Lead Sponsor
- Furiex Pharmaceuticals, Inc
- Target Recruit Count
- 161
- Registration Number
- NCT01128530
- Locations
- 🇺🇸
Furiex Research Site, Webster, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath